No results for ‘’
Venus Remedies Ltd
NSE: VENUSREM BSE: 526953
â‚ą1616.30
(0.49%)
Thu, 17 Sept 2026, 09:33 am
Market Cap (in Cr)2181.83
PE Ratio18.60
Dividend0.61
Health Technology
Pharmaceuticals: Major
24.5KVenus Remedies Analysis
dividend
- Unable to calculate sustainability of dividends as Venus Remedies has not reported any payouts.
- Unable to evaluate Venus Remedies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Venus Remedies's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Whilst loss making Venus Remedies has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -52.4% per year.
- Whilst loss making Venus Remedies has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
- Debt is well covered by operating cash flow (31.8%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 1.3x debt.
- Venus Remedies's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (68.3% vs 57% today).
- Venus Remedies's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
- Venus Remedies is making a loss, therefore interest payments are not well covered by earnings.
- Venus Remedies's level of debt (57%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- The average tenure for the Venus Remedies board of directors is over 10 years, this suggests they are a seasoned and experienced board.
- Pawan's compensation has been consistent with company performance over the past year, both up more than 20%.
- Pawan's remuneration is higher than average for companies of similar size in India.
- The average tenure for the Venus Remedies management team is less than 2 years, this suggests a new team.
misc
- Venus Remedies is not covered by any analysts.
- Venus Remedies has significant price volatility in the past 3 months.
past
- Unable to compare Venus Remedies's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Venus Remedies does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- It is difficult to establish if Venus Remedies has efficiently used its assets last year compared to the IN Pharmaceuticals industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Venus Remedies improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
- It is difficult to establish if Venus Remedies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- Unable to compare Venus Remedies's 1-year growth to the IN Pharmaceuticals industry average as it is not currently profitable.
value
- Venus Remedies's share price is below the future cash flow value, and at a moderate discount (> 20%).
- Venus Remedies's share price is below the future cash flow value, and at a substantial discount (> 40%).
- Venus Remedies is good value based on assets compared to the IN Pharmaceuticals industry average.
- VENUSREM outperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- VENUSREM outperformed the Market in India which returned -14.5% over the past year.
- NSEI:VENUSREM is up 8% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- NSEI:VENUSREM is up 8% along with the India market (8%) over the past month.
- Venus Remedies is loss making, we can't compare its value to the IN Pharmaceuticals industry average.
- Venus Remedies is loss making, we can't compare the value of its earnings to the India market.